Overview of the Mutational Landscape in Primary Myelofibrosis and Advances in Novel Therapeutics

Myelofibrosis: diagnosis and treatment

“…Leukocytosis and thrombocytosis may be observed. These patients also experience increased risk of thrombosis and second neoplasms 3,10,11 .…”

Mielofibrosis: diagnóstico y tratamiento

“…Se puede observar leucocitosis y trombocitosis. Estos pacientes también experimentan riesgo incrementado de trombosis y segundas neoplasias 3,10,11 .…”

Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms

“…HSP is a family of ATP-dependent, cytoprotective, stress-response protein chaperones that bind and stabilize client proteins in their functional active form, thus maintaining survival advantage of MPN cells. [ 248 , 272 , 273 , 274 , 275 ]. HSP90 chaperones JAK2 while HSP27 modulates STAT5 phosphorylation, making them therapeutic targets in MPN [ 273 ].…”

“…This suggests that HSP90-mediated JAK/STAT pathway inhibition may be short-lived [ 248 ] ( Table 3 ). An important finding is that the combination of JAK inhibitor (TG101209) with AUY922 acted synergistically to induce apoptosis in primary MF CD34 + cells [ 273 , 274 , 275 ]. The pro-apoptotic effect was also seen in JAK1/2 inhibitor-resistant cells [ 275 ], suggesting a possible solution to overcome ruxolitinib resistance.…”